Cleveland BioLabs, Inc. (
Representatives of Roswell Park Cancer Institute and the Buffalo Niagara Medical Campus, as well as several New York State legislators will join Cleveland BioLabs management and staff for the festivities.
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs and the entire senior management team express their gratitude to Roswell Park Cancer Institute, the Buffalo Niagara Medical Campus and Buffalo Niagara Enterprise for welcoming the Company to Buffalo and supporting its relocation efforts.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our periodic filings with the Securities and Exchange Commission.
Contacts:
The Global Consulting Group
Rachel Levine
T: (646) 284-9439
E: rlevine@hfgcg.com